Showing results (1-10 of 114) with videos related to
Sort By:
Pageof 12
Circulation|March 14, 2001
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) TrialS R Steinhubl, S G Ellis, K Wolski, et al.Journal of the American College of Cardiology|November 11, 1998
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctionsS R Steinhubl, M S Lauer, D P Mukherjee, et al.The Annals of Thoracic Surgery|August 31, 2000
Antiplatelet agents in cardiology: the choice of therapyS R SteinhublCirculation|February 9, 1999
Rapid platelet-function assay: an automated and quantitative cartridge-based methodJ W Smith, S R Steinhubl, A M Lincoff, et al.Circulation|November 11, 1999
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary interventionS R Steinhubl, K Kottke-Marchant, D J Moliterno, et al.The Journal of Invasive Cardiology|December 9, 1993
Patients at high risk for ischemic complicationsA M LincoffThe American Journal of Cardiology|November 11, 1998
Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularizationA M LincoffJournal of Thrombosis and Thrombolysis|September 27, 2000
Clopidogrel and coronary stenting: what is the next question?S A Moore, S R SteinhublHeart and Vessels|January 1, 1997
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable anginaS R Steinhubl, D J MoliternoJournal of Thrombosis and Haemostasis : JTH|February 11, 2005
Variability in response to aspirin: do we understand the clinical relevance?C L Campbell, S R SteinhublPageof 12